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Abstract: Korea has continuously sought to improve its regulatory environment for clinical trials and has invested 
heavily in clinical trial infrastructure and technology since the early 2000’s. A strategic investment through the Korea 
National Enterprise for Clinical Trials (KoNECT) program began in 2007 and grew to encompass a network of regional 
clinical trial centers to promote clinical trial capabilities and human resource development. In early 2014, KoNECT 
became a permanent organization focused on the advancement of the country's clinical trial industry. This was followed 
by the establishment of the Korea Clinical Trials Global Initiative (KCGI) and the KoNECT Collaboration Center for 
global clinical trials (KCC). KCGI and KCC are now at the forefront of KoNECT’s efforts to promote higher operation-
al efficiency in the country’s clinical trials. These new initiatives in clinical research are undertaking multichannel ap-
proaches to pursue a cohesive international collaboration model between government, industry and academia for the 
development of new treatments and improved patient care. 
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1. Introduction 
n the early 2000’s, a standard clinical trial autho-
rization (CTA) process was established in Korea 
to facilitate the clinical development of new drugs 
by streamlining the regulatory requirements for clini-
cal trial approval. Together with improvements to 
Korea’s clinical trial approval system and revision of 
Korean Good Clinical Practice (KGCP) to align with 
the international ICH GCP guidelines, this enabled the 
country to participate in larger multinational clinical 
trials funded by global sponsors. The bridging re-
quirements for registering foreign developed medicin-
al products were also synchronized by adopting the 
ICH E5 guidelines.  
In addition to extensive regulatory reform, the Ko-
rean government accelerated investments in clinical 
trial infrastructure to strengthen local capabilities for 
new drug development, attract a greater number of 
global clinical trials to Korea, and facilitate earlier 
patient access to new treatments while bolstering the 
country’s economy.  
The Regional Clinical Trial Centers (RCTC) pro-
gram was initiated by the Korean Ministry of Health 
and Welfare (MOHW) to aid the establishment of 
clinical trial support systems, including phase 1 units. 
The RCTC program also sought to improve the pro-
fessional quality of the clinical trial workforce at ma-
jor academic medical institutions by awarding USD 5 
million for five years to each major center.  
I 
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In December 2007, the Korea National Enterprise 
for Clinical Trials (KoNECT) was established by the 
MOHW as a seven-year program to further develop 
clinical trial infrastructure to cope with the increasing 
demand for clinical trials in Korea. The organization 
continued to stringently select additional centers to 
bring the total number of RCTCs in the country to fif-
teen centers and assessed their performance based on 
predefined qualitative and quantitative goals. Ko-
NECT was also responsible for the launching of a 
number of clinical trial technology development 
projects, and operated the ‘KoNECT Clinical Trial 
Training Academy’ to provide free training for the 
clinical trial workforce.  
The impetus of regulatory reform combined with 
the KoNECT program contributed to a dramatic in-
crease in both domestic studies and multinational 
clinical trials by global sponsors in Korea. The num-
ber of Investigational New Drug (IND) approvals for 
sponsor-initiated multinational clinical trials grew 
from 5 in 2000 to 291 by the end of 2014, and domes-
tic trials rose to 361 from 28 during the same period 
(Figure 1).  
With the completion of the initial seven-year Ko-
NECT program in early 2014, KoNECT’s mission 
was extended and the organization was established as 
a legal entity tasked with fostering clinical trial colla-
boration and improving the country’s economy. With 
continuous investments in infrastructure and human 
resources, the Korean government has identified new 
drug development capability as a key driver for Ko-
rea’s future economic growth. New clinical trial initi-
atives, namely the Korea Clinical Trials Global Initia-
tive (KCGI) and the KoNECT Collaboration Center 
for global clinical trials (KCC), were launched in 2014 
and 2015, respectively. Since approval of the first new 
drug developed in Korea in 1999, 24 new drugs have 
followed the same path. 
2. KoNECT 
KoNECT was established by the MOHW in 2007 and 
mandated to lead the RCTC program and two addi-
tional projects. The ‘KoNECT Clinical Trial Training 
Academy’ is an education and training program for 
clinical trial personnel while the ‘New Clinical Trial 
Technology Development’ program is focused on 
clinical trial promotion. KoNECT has completed the 
designation of eight RCTCs in the Seoul metropolitan 
area, three in Busan and four in other areas of Korea. 
These 15 RCTCs have served as core sites, responsi-
ble for over sixty percent of the total number of clini-
cal trials conducted in the country[1]. In 2010, Seoul 
was ranked as the most active city in clinical trials in 
the world in terms of clinical trial sites registered at 
ClinicalTrials.gov[1] and has maintained the top posi-
tion in subsequent years till 2014. 
The KoNECT Clinical Trial Training Academy was 
designed to offer courses on clinical trial topics in-
cluding GCP for clinical investigators, clinical re-
search coordinators (CRCs), clinical trial pharmacists, 
clinical research associates (CRAs), data managers/ 
biostatisticians, pharmaceutical medicine specialists 
and clinical pharmacologists. The cumulative number 
of trainees entering the programs over the past 6 years 
has reached 45,000, including the 10,628 trainees 
 
 
 
Figure 1. Korean government’s initiatives and number of IND approved by Ministry of Food and Drug Safety (MFDS). 
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who completed the courses. The curriculum consists 
of lectures and hands-on practice lasting 16 hours or 
more. Part of the continuing mission of the new Ko-
NECT is to advance the country's capabilities for 
clinical trials as a solid foundation for clinical devel-
opment by the Korean pharmaceutical industry. 
In addition, there are ongoing efforts to develop a 
cohesive collaboration model with national and inter-
national partners seeking higher operational efficiency 
and scientific improvements for more effective clini-
cal trials. Building international and regional networks 
to address the unmet medical needs, especially for 
regional conditions, is also included in its missions.  
Current core activities of the new KoNECT include 
clinical trial policy development and providing expert 
recommendations to the government and other stake-
holders, the generation and provision of statistics ana-
lyzing clinical trials activities and infrastructure, and 
the strengthening of the industry’s overall competi-
tiveness, including local CROs. KoNECT runs an ac-
creditation program for local CROs, auditing selected 
priority areas of site management, project manage-
ment, data management and medical writing. The ob-
jective of the accreditation program is to help local 
CROs to continuously improve by providing them 
with feedback through the evaluation process asso-
ciated with accreditation.  
KoNECT continues to provide year-round training 
courses for diverse professionals working in the clini-
cal trial industry at different levels such as clinical 
investigators, clinical trial pharmacists, CRAs, CRCs, 
and data managers. Training programs are offered at 
various levels to reflect differences in the experience 
of the participants[2]. The organization also offers cer-
tification programs for CRAs and CRCs, and has de-
veloped a Learning Management System (LMS) to 
efficiently manage all training and certification 
records. 
For international partners seeking collaboration, 
KoNECT collects, analyzes and provides high-level 
information on the country’s clinical trial infrastruc-
ture and capabilities. In September 2015, a new initia-
tive called the KoNECT Collaboration Center for 
global clinical trials (KCC) was launched to serve as a 
matrix of collaborative efforts seeking to engage na-
tional and international partners in clinical trials.  
3. Korea Clinical Trials Global Initiative (KCGI) 
Korea has made considerable progress in the field of 
global clinical development over the past decade 
through joint efforts by academia, industry and gov-
ernment. However, it is recognized that emerging 
challenges arising from changes in the global drug 
development paradigm and the global clinical trial 
environment must be proactively dealt with. Major 
issues in new drug development include low produc-
tivity, high attrition rates, low efficiency, high costs, 
and lengthy development timelines. There exists a 
number of conceptual and operational hurdles that are 
particularly apparent in the early phase clinical trials 
such as limited time and resources, difficulties in 
study design to adequately demonstrate proof of con-
cepts/mechanisms/safety, selection or development of 
appropriate biomarkers or surrogate endpoints, tech-
nical complexities, and scientific rigor. 
Korea’s success in global clinical development 
during the past decade has primary centered around 
late clinical development[3]. In addition to a good track 
record in late phase trials, unique features of the coun-
try’s medical environment and healthcare system 
place it in an advantageous position to conduct early 
phase trials for global drug development programs. 
These factors include the quality of medical care and 
infrastructure such as hospital facilities and equipment. 
In addition, university hospitals in the country are 
concentrated in highly populated cities providing large 
patient pools, and staffed by highly educated and mo-
tivated investigators holding university faculty posi-
tions. Clinical trial centers in these university hospitals 
are often located on hospital premises and operated by 
dedicated hospital personnel. 
In order to ensure continued progress in new drug 
development and to increase the number of high val-
ue-added early phase trials, KCGI was launched by 
the MOHW in 2014. The goals of KCGI include the 
strengthening of global competitiveness in the clinical 
trial industry through the development and support of 
growth engines for the industry, and to promote scien-
tific advancement and operational efficiency in clini-
cal trials through the development of new research 
methods that incorporate convergence technologies. 
KCGI is a government-funded R&D program that 
supports the setup of research infrastructure and oper-
ational systems in CTCs at major leading academic 
medical institutions. These institutions must each have 
an established research governance overseeing inter-
nationally-accredited human research protection pro-
grams and outstanding clinical trial performance. 
KCGI’s Global Centers of Excellence (GCE) program 
is tasked with supporting investments in research in-
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frastructure to focus the efforts of CTCs to become 
globally competitive in the early phase development 
in specialized therapeutic areas or areas of unmet 
medical needs. To date, the GCE program has selected 
five university hospital CTC consortia, each of which 
is composed of two to five CTCs located at separate 
university hospitals (Figure 2). Each consortium rece-
ives USD 2 million per year for 5 years. KCGI seeks 
to promote operational excellence in early phase clin-
ical trials through efficiency, maximization of com-
bined and shared resources, and innovation in trial 
R&D. Furthermore, KCGI also facilitates relationship 
building between clinical and nonclinical experts from 
academia and industry in the earliest possible stages of 
new drug development in order to minimize future 
failures and difficulties in clinical development. Five 
consortia of GCE have their own focal areas of spe-
cialization and are making efforts to collaborate on 
specific aspects of clinical trials. Currently, a number 
of tools have been developed or are in use, including: 
mutual recognition systems for IRB review processes, 
common IRB review application forms, eCRFs which 
enable auto-migration of Order Communication Sys-
tem (OCS)/Electronic Medical Records (EMR) data, 
and a clinical data retrieval system for DB (Data 
Base)-driven feasibility assessment. Pooling of ano-
nymized patient data and the establishment of inves-
tigator networks for defined therapeutic areas among 
institutions within each consortium provide a strong 
foundation for improving early phase trial produc-
tivity. 
The Convergence Technologies for Clinical Trials 
Project provides funding for the development of new 
clinical trial technologies that improve efficiency and 
accuracy, or reduce redundancies, errors, time and 
costs. 
To better prepare for the wider changes taking pace 
in the global clinical environment, KCGI brings GCE 
personnel together for opportunities to exchange in-
formation and share best practices between the con-
sortia. Each unique system of consortia serves as an 
open platform that can accept the addition of other 
CTCs. A regular forum is held between institutions 
that are developing new convergence technologies to 
share updated information. 
KCGI is focused on the improvement of research 
infrastructure, sharing of knowledge among centers, 
and the establishment of inter-institutional investigator 
 
 
 
Figure 2. Global Centers of Excellence Project by Korea Clinical Trials Global Initiative (R&D grant of Ministry of Health and 
Welfare) supports 5 consortia (different colored boxes) located around the nation. 
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networks, patient databases and registries as a national 
CTC consortium. The ultimate goal of these efforts is 
to provide a highly capable clinical trial infrastructure 
for both global and domestic pharmaceutical compa-
nies in their development of new drugs, with a strong 
focus on early phase development, in addition to the 
facilitation of academic clinical research to improve 
healthcare quality.  
4. KoNECT Collaboration Center (KCC) 
The ineffectiveness and inefficiencies that the clinical 
trial industry faces remain major challenges world-
wide. Recent statistics show that on average, one third 
of all Phase III studies are terminated due to enroll-
ment difficulties, and nearly 80 percent of clinical 
trials fail to meet their enrollment timelines[4], indi-
cating that trial planning and management is one of 
the most critical areas for R&D productivity. Fur-
thermore, difficulty in obtaining reliable information 
on the regulatory environment and service providers 
in a new region or country hinders potential sponsors 
from efficiently assessing new trial sites. KoNECT 
provides practical services and reliable information to 
fulfill these needs, and enhance the feasibility of con-
ducting clinical trials in Korea to make significant 
contribution to the multi-regional clinical trials 
(MRCT) or global clinical planning by improving the 
ability of sponsors to engage in informed decision 
making. 
With the support of the Korean government, the 
KoNECT Collaboration Center for global clinical tri-
als (KCC) was formally opened on September 1, 2015. 
KCC constitutes an unprecedented systematic clinical 
trial support system designed to assist sponsors in 
their MRCT planning by providing helpful services 
and information. 
Major services and features of the KoNECT Colla-
boration Center include: the KoNECT Integrated clin-
ical trial Information System (KIIS), One-Stop Shop 
services for clinical trial planning in Korea, a business 
center with administrative support, a Korean clinical 
trial interactive gallery and liaison service with clini-
cal trial networks.  
4.1 KIIS (KoNECT Integrated clinical trial  
Information System) 
Concerted efforts are being made by the clinical trial 
industry to tackle inefficiencies in feasibility assess-
ment to achieve more data-driven than opinion-based 
evaluations[5]. Feasibility refers to the identification 
and quantification of risks in clinical trial planning, 
including country and site selection, as well as re-
sourcing partners[4]. According to a recent survey 
conducted in Europe[6], more than 80% of 253 res-
pondents agreed that they are much more likely to 
select a trial site if all of the relevant investigator and 
site specific information is made easily available to 
them. This indicates that uncertainty and opinion- 
based practices are still prevalent in feasibility as-
sessment process. The ongoing need for information 
sufficient to make informed decisions during feasibil-
ity evaluations is increasing in emerging economies, 
as more pharmaceutical companies are moving into 
these regions[7]. KIIS aims to address these needs by 
creating an information resource that multiple stake-
holders who intend to conduct clinical trials in Korea 
can use to collaborate with improved efficiency pri-
marily during the feasibility assessment period.  
KIIS consists of a web-based information archive 
established and operated by KoNECT. It provides in-
formation on the Korean pharmaceutical market and 
healthcare system, updated by investigators, clinical 
trial centers, and clinical trial service providers, in-
cluding CROs. KIIS currently provides comprehen-
sive information on six major topics including: (i) in-
dustry overview, (ii) ongoing and completed clinical 
trials in Korea, (iii) epidemiology data, as well as pa-
tient numbers and distribution data derived from na-
tional medical insurance claims in accordance with 
ICD10 (International Classification of Diseases), (iv) 
Korean treatment and diagnosis guidelines, (v) site 
and investigator registry, and (vi) KoNECT partners 
including service providers (Table 1). KIIS is accessi-
ble through the website of the KCC[8] and different 
levels of authorization are granted to access various 
levels of information. An online search functionality 
with multiple predefined conditions and keywords 
has been implemented to efficiently navigate the data.  
4.2 KCC Supports for Clinical Trial Planning in 
Korea  
The KCC supports the planning and conduct of clini-
cal trials in Korea by providing information and other 
support when requested. The information covers an 
overview of Korea’s healthcare system and industry, 
the country’s clinical trial sites and corresponding 
experience in clinical trials, IND application and ap-
proval processes and requirements, and other relevant 
regulations. KCC also has the capacity to coordinate 
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Table 1. Content of KIIS 
Category Content 
Industry Overview 
 
Facts and figures on macroeconomic indicators, including datasets for the healthcare system, pharmaceutical 
and clinical trial industries of Korea. 
Epidemiology and Patient Dist-
ribution Data  
 
Published Korean epidemiology data relevant to clinical research. 
Patient numbers and distribution data by ICD10 derived from the HIRA (National Health Insurance Review 
and Assessment) claims database. 
Clinical Trial Experience  Database collating all completed and ongoing clinical trials in Korea listing and comparing trials by site and 
indication. 
Clinical Trial Site Information  
 
Information on clinical trial sites, including facilities, human resources, early phase research capabilities, core 
research technologies, and clinical trial experience. 
Investigator Information  Information on Korean investigators including clinical trial experience, research interests, and training records. 
KoNECT Partners  
 
Information on KoNECT partners including clinical trial networks, CROs, local pharmaceutical companies, 
service providers and consultants. 
 
meetings between sponsors and local service providers 
in response to specified requests from sponsors.  
4.3 Korea Clinical Trial Interactive Gallery 
A tour of the Korean Clinical Trial Interactive Gallery 
at the KCC is available for those seeking to learn more 
about Korea’s clinical trial infrastructure. The exhibi-
tion details the development history, capabilities and 
experience of the Korean clinical trial industry and 
features major clinical trial centers. This is designed to 
showcase the country’s clinical trial capabilities and en-
vironment to international sponsors in an effective way. 
5. Conclusion 
Over the past few decades, Korea has made concerted 
effort to establish a favorable and harmonized regula-
tory environment for global clinical trials, and in-
vested heavily in clinical trial infrastructure. The suc-
cess of this first phase of transformation has relied 
upon strong support and financial commitment from 
the Korean government. The second phase of trans-
formation, which is now being spearheaded by the 
new KoNECT, is intended to further strengthen the 
nation’s clinical trial capacity and capability for global 
collaboration with higher efficiency and better science 
by undertaking multichannel approaches. The purpose 
is to achieve a cohesive collaboration model between 
Korean government, industry and academia for im-
proved cooperation with international partners in order 
to develop new treatments and improve patient care. 
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